Skip to main content
Canna~Fangled Abstracts

Effects of a Peripherally Restricted Hybrid Inhibitor of CB1 Receptors and iNOS on Alcohol Drinking Behavior and Alcohol-Induced Endotoxemia

By August 22, 2021August 29th, 2021No Comments
. 2021 Aug 22;26(16):5089.

doi: 10.3390/molecules26165089.

Luis Santos-Molina 1, Alexa Herrerias 1, Charles N Zawatsky 2, Ozge Gunduz-Cinar 3, Resat Cinar 2, Malliga R Iyer 4, Casey M Wood 4, Yuhong Lin 5, Bin Gao 5, George Kunos 1, Grzegorz Godlewski 1
Affiliations 

Abstract

Alcohol consumption is associated with gut dysbiosis, increased intestinal permeability, endotoxemia, and a cascade that leads to persistent systemic inflammation, alcoholic liver disease, and other ailments. Craving for alcohol and its consequences depends, among other things, on the endocannabinoid system. We have analyzed the relative role of central vs. peripheral cannabinoid CB1 receptors (CB1R) using a “two-bottle” as well as a “drinking in the dark” paradigm in mice. The globally acting CB1R antagonist rimonabant and the non-brain penetrant CB1R antagonist JD5037 inhibited voluntary alcohol intake upon systemic but not upon intracerebroventricular administration in doses that elicited anxiogenic-like behavior and blocked CB1R-induced hypothermia and catalepsy. The peripherally restricted hybrid CB1R antagonist/iNOS inhibitor S-MRI-1867 was also effective in reducing alcohol consumption after oral gavage, while its R enantiomer (CB1R inactive/iNOS inhibitor) was not. The two MRI-1867 enantiomers were equally effective in inhibiting an alcohol-induced increase in portal blood endotoxin concentration that was caused by increased gut permeability. We conclude that (i) activation of peripheral CB1R plays a dominant role in promoting alcohol intake and (ii) the iNOS inhibitory function of MRI-1867 helps in mitigating the alcohol-induced increase in endotoxemia.

 

Keywords: CB1 receptor antagonist, MRI-1867, alcohol craving, cannabinoid, drinking in the dark, hybrid ligand, iNOS inhibitor, intracerebroventricular administration, rimonabant, two-bottle paradigm

Conflict of interest statement

R.C., M.R.I. and G.K. are listed as coinventors on a US patent (US 9,765,031 B2) covering MRI-1867 and related compounds.

Figures

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

References

    1. Murray C.J.L., Aravkin A.Y., Zheng P., Abbafati C., Abbas K.M., Abbasi-Kangevari M., Abd-Allah F., Abdelalim A., Abdollahi M., Abdollahpour I., et al. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223–1249. doi: 10.1016/S0140-6736(20)30752-2. – DOI – PMC – PubMed
    1. McGinn M.A., Pantazis C.B., Tunstall B.J., Marchette R.C.N., Carlson E.R., Said N., Koob G.F., Vendruscolo L.F. Drug addiction co-morbidity with alcohol: Neurobiological insights. Int. Rev. Neurobiol. 2021;157:409–472. doi: 10.1016/bs.irn.2020.11.002. – DOI – PubMed
    1. Nordeck C.D., Riehm K.E., Smail E.J., Holingue C., Kane J.C., Johnson R.M., Veldhuis C.B., Kalb L.G., Stuart E.A., Kreuter F., et al. Changes in drinking days among US adults during the COVID-19 pandemic. Addiction. 2021 doi: 10.1111/add.15622. – DOI – PubMed
    1. Koob G.F., Volkow N.D. Neurobiology of addiction: A neurocircuitry analysis. Lancet Psychiatry. 2016;3:760–773. doi: 10.1016/S2215-0366(16)00104-8. – DOI – PMC – PubMed
    1. Morley K.C., Perry C.J., Watt J., Hurzeler T., Leggio L., Lawrence A.J., Haber P. New approved and emerging pharmacological approaches to alcohol use disorder: A review of clinical studies. Expert Opin. Pharmacother. 2021;22:1291–1303. doi: 10.1080/14656566.2021.1892641. – DOI – PubMed

Leave a Reply